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Abstract
Introduction: In modern medicine the cause of infertility is believed to be
immune mechanism disorders as well as immune over-reactivity. The objective
of this thesis is to evaluate the diagnostic usefulness of measuring the
concentration of soluble TNF-α receptors p55 and p75 in women with primary
infertility.
Material and methods: Examination subjects: 41 female patients with primary
sterility in the period January-September 2005. The control group consisted of
13 female patients. For identification of soluble receptors’ p55 and p75 TNF-α
concentration was used commercial ELISA kits. Quantitative in vitro method of
hormone identification in blood serum of plasma (ECLIA) has been used to
estimate hormone concentration. Results have been analyzed with Student’s 
t-test, Wilcoxon’s test, Fisher’s exact test and Spearman’s test. P value < 0.05
was considered significant.
Results: There is no significant statistical relation between concentration of
soluble p55 and p75 TNF-α receptors and age, BMI index, or length of periods.
In the case of soluble p75 TNF-α receptor a statistical correlation with length
of period was found (p = 0.004). From the statistical point of view, the most
advantageous relation was found in the case of p75 TNF-α soluble receptor and
thickness of endometrium (p = 0.007) as well as the correlation of p55/p75
soluble receptors (p = 0.05). The statistical analysis of correlations between
TNFR1 and TNFR2 receptors and concentration of hormones FSH, LH, PRL, 
E2 and testosterone showed no dependence of TNFR1 and TNFR2 receptor
concentrations and concentrations of examined hormones. Statistical analysis
of relations of TNFR1/TNFR2 receptor concentrations revealed a significant
correlation between these receptors and concentration of LH (p = 0.05).
Conclusions: The correlation between endometrium thickness, size of dominating
vesicle and concentration of LH compared to concentrations of soluble TNF-α
receptors p55 and p75 and their ratio might condition the time of survival of
the vesicle or lead to excessive expression of its atresion-leading conditions. 
Key words: tumour necrosis factor, immune mechanism, primary sterility, soluble
TNF-α receptor p55, soluble TNF-α receptor p75.
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Introduction
Infertility is a significant epidemiological problem
that is particularly prominent in developed
countries. In Poland, according to epidemiological
data, infertility or inability to deliver occurs in about
1 million (18-20%) married couples [1]. 
The sterility problem has been considered by
WHO (World Health Organisation) as a social
disorder [2].
While fertility depends on many organic,
hormonal and psychological factors and on male
sterility, modern medicine tends to seek reasons in
failures within mechanisms of the immune system
as well as its hyperactivity [1].
The aetiology of sterility with its basis in the
immune system is still not well understood. Two
soluble receptors, p55 (TNFR1, CD 120a, p55α, 
55-kDa protein, TNFRSF1, type 1 TNF-α) and p75
(TNFR2, CD 120b, p75α, 75-kDa protein, TNFRSF1B,
type 2 TNF-α), are likely to be involved in the
pathomechanisms of sterility. These two receptors
seem to be present in most human cells and they
interact with TNF-α (tumour necrosis factor α,
cachectin), which results in signal transduction and
expression of NF-B and c-Jun. These two factors are
in turn responsible for expression of genes
responsible for growth and death of a cell, cancer
formation, the immune response, cellular stress and
inflammation. Molecules from the TNF subfamily
are expressed in almost every cell and participate
in most regulatory processes in the human body 
[3-11].
Recently it is thought that p55 TNF-α receptor is
responsible for inducing apoptosis, whereas p75
TNF-α stimulation is involved in cellular
proliferation, and there have been many
antagonistic models of the two receptors reported
in the literature. The two proteins differ in mass,
glycosylation level, affinity for TNF and inner-cell
domain structure. Due to these differences,
signalling by the two receptors provides different
information to a cell. The inner-cell part of the p55
TNF-α receptor consists of a 70 amino acid long
domain, known as the death domain (DD), which
can induce apoptosis: Apo-1/ Fas (CD95), DR2, DR3,
TRAIL-R1 (DR-4), TRAIL-RZ (DR5), DR6. TNF receptors
are present on almost every cell – TNFR2 is found
in leukocytes and endothelial cells, whereas TNFR2
is present in endodermal cells. Lymphocytes,
fibroblasts and endothelial cells have both of the
TNF receptors on their surfaces. Both are also
present in serum, which results in absorption of
TNF from blood and decrease of its biological effect
[6, 12-14].
The direct action of various TNFs on the human
immune system is known to be due to their
induced release from lymphocytes (such as IFN-γ)
and from macrophages. The latter release IL-1, 
IL-6, GM-CSF, G-CSF, M-CSF, PDGF, NGF, EGF and
PAF (platelet activating factor), IFN-β, and many
products of the arachidic acid cycle. It has been
observed that GM-CSF is often present within
oocytes which have not been fertilized. Activation
of macrophages and a few other cells by increased
levels of GM-CSF within oocytes that fail to develop
properly suggests a possible relationship between
the immune system and the endocrine system with
the involvement of cytokines. It was shown that
increased GM-CSF concentration remains in
correlation with female infertility, due to
macrophage activation and decreased capability of
oocytes to be fertilized. GM-CSF can also influence
the antigen presentation by male cells and the
immune response of female cells and of tissues
during transplantation. TNF also induces expression
of MHC type I and type II proteins [13, 15].
According to the literature, proinflammatory
cytokines (IL-1β, IFN-γ, TNF-α) participate in
autocrine and paracrine regulation of growth and
differentiation of the placenta, implantation of the
fertilised egg cell and the early stage of embry  o  -
genesis [1, 16, 17].
Lack of cytokines with Th2 activity or too high
amounts of cytokines of type Th1 disrupts the
proper implantation process. The hormonal system,
cooperating with the immune system, has
a significant role in vesicular development (their
recruitment, selection and domination) and later in
fertilization and implantation. Hormonal factors that
regulate ovarian vesicular development consist of:
gonadotrophins (LH, FSH), prolactin, ovarian steroids
(oestradiol, androgens, progesterone), ovarian
peptides and proteins (inhibin, activin, follistatin)
and a spectrum of insulin-like growth factors (IGF).
Research has also shown the involvement of growth
factors such as: epithelial growth factor (EGF),
transforming growth factor α (TGF-α), platelet-
derived growth factor (PDGF), fibroblast growth
factor (FGF), transforming growth factor β (TGF-β),
interleukin, and vascular endothelial growth factor
(VEGF) [15, 18].
There is a whole array of factors that influence
survival of an egg cell, among them IGF-1, which is
produced by granulocytes and which stimulates
vascular cells to produce EGF/TGF, which halts
apoptosis of granulocytes. FSH acts on vascular cells
to increase the synthesis of TGF/EFG-α and release
factors that stimulate vascular cells to produce
TGF/EFG-α as well. IGF-1, produced by granulocytes,
also stimulates vascular cells, which leads to an
increase in EGF/TGF concentrations. These factors,
in a paracrine fashion, act on granulocytes,
inhibiting their apoptosis [15, 19-22].
The aim of this study was to evaluate the
concentration of soluble p55 and p75 TNF-α
receptors in women with primary sterility.
Do soluble p55 and p75 TNF-α receptor concentrations play a role in women with primary sterility?Material and methods
Studies were carried out on 41 examined female
patients (age 17 to 42) with primary sterility, under
treatment in the Department of Mother’s and Child’s
Health of Poznan University of Medical Sciences in
the period January-September 2005. The materials
were collected during regular, diagnostic
examinations of these patients, after they had been
assessed for ovulation and in parallel with hormonal
examinations. Because of the small control group,
there were no subgroups formed. The control group
consisted of 13 female patients who had checked in
for routine control examinations. Eight of these
women had already delivered once before and five
of them had delivered twice. Patients, upon arrival
at the hospital, had their reproductive organs
examined with Aloka SSD 5000 with vaginal probe
detector ultrasound with a frequency of 7.5 MHz.
Blood samples were taken from the patients (initially
for routine, hormonal studies carried out in parallel
to investigate sterility – described later on),
centrifuged and the serum frozen at –70°C.
A commercially available ELISA kit (enzyme-linked
immunosorbent assay) was used to label p55 and
p75 TNF-α receptors. TNF-α-R1 and TNF-α-R2 were
assayed using Quantikine (R&D Systems, USA) with
sensitivity 0.77 and 1.0 pg/ml respectively. Extinction
coefficient readouts were taken at 450 nm with Bio-
Tek Instruments, Inc. EL x 808, Ultra Microplate
Reader (620-650 nm correction). FSH, LH, E2, PRL and
testosterone concentrations were determined using
an Elecsys analyser from Roche Diagnostic.
Concentrations of various plasma and serum
hormones were determined using ECLIA (electro  -
chemiluminescence immunoassay).
Statistical analyses were carried out using
SigmaStat 3.1 (Systat Inc, USA). Results are
presented as mean values ± standard deviation
(SD). Wilcoxon test was used to compare
differences, since there was no normal distribution
shown in Kolmogorov-Smirnov test. Occurrence
frequencies were characterised with a Fisher’s exact
test. Value correlations were analysed with
Spearman’s test. Values with p < 0.05 were
considered as statistically significant. The
experiments were approved by the Medical
University Bioethical Committee.
Results
Mean age and BMI (body mass index) values
indicate no difference between the control group
and the study subjects – see Table I. Wilcoxon’s test
showed no statistically significant difference
between mean age, BMI and the length of the
menstrual cycle among patients from the analysed
groups.
Results from the statistical analysis (Table II)
show no significant statistical relationship between
p55 and p75 TNF-α receptor concentrations, mean
age, BMI, length of menstrual cycle and duration of
menstruation. Therefore, there is no correlation
between these parameters and the concentration
of p55 and p75 TNF-α receptors.
In the case of soluble p75 TNF-α receptor, it was
shown to correlate with the frequency of occurrence
of the cycles (p = 0.004). Similar tendencies were
Parameters Sterility (n = 28) Control (n = 13) Wilcoxon test p
Age [year] 28.0 ±4.1 30.4 ±8.6 0.49
BMI [kg/m2] 21.5 ±2.7 21.6 ±3.0 0.91
Length of menstrual cycle [day] 32.4 ±9.4 28.7 ±1.3 0.74
Regularity of cycle [%] 21/28 12/13 0.06*
Mean duration of bleeding [day] 5.6 ±1.0 6.4 ±2.6 0.46
sICAM-1 [ng/ml] 200.1 ±60.7 210.0 ±63.7 0.64
FSH [mIU/ml] 7.96 ±5.84 10.26 ±12.47 0.28
LH [mIU/ml] 14.74 ±15.60 10.43 ±9.04 0.39
Oestradiol [pg/ml] 142.8 ±129.9 135.6 ±123.1 0.84
Prolactin [ng/ml] 22.7 ±13.4 29.9 ±50.8 0.21
Testosterone [ng/ml] 0.47 ±0.16 0.48 ±0.21 0.93
p55 [pg/ml] 1489 ±234 1397 ±180 0.22
p75 [pg/ml] 3889 ±117 2748 ±516 < 0.001
p55/p75 0.40 ±0.08 0.52 ±0.06 < 0.001
*Fisher’s exact test
Table I. Comparison of various parameters obtained from patients with primary sterility and the control group
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obtained when comparing the p55/p75 ratios 
(p = 0.01). The most favourable correlation was
found between concentration of soluble p75 
TNF-α receptor, thickness of endometrium 
(p = 0.007) and the ratio of p55/p75 receptor
concentrations (p = 0.05). Similar values were
obtained for p55/p75 ratio and the size of growth
ovarian vesicular (p = 0.04).
Statistical analysis of the correlations between
TNFR1 and TNFR2 receptors and FSH, LH, PRL, E2,
and testosterone concentrations showed no
relationships (Table II).
A significant relationship was found between the
TNFR1/TNFR2 concentration ratio and the
concentration of LH (p = 0.05).
Discussion
Many clinical experiments and observations
have shown that TNF-α has immunoregulatory
properties, influencing directly and indirectly 
the processes within the immune system [1, 6, 13,
23, 24].
According to Tchórzewski [25] even the smallest
concentrations of TNF-α can increase the immune
response to antigens on T lymphocytes. This
cytokine also stimulates phagocytic processes,
especially oxidative metabolism and neutrophil
aggregation, and increases the expression of
integrin (CD11/CD18).
According to Emdo and Baird [26] TNF-α takes
part in inhibition of 17-α-hydroxylase/17,20-lyase,
Parameter Receptor p55 Receptor p75 p55/p75
Age [year] –0.20, p = 0.23 0.01, p = 0.93 0.01, p = 0.93
BMI [kg/m2] 0.06, p = 0.67 0.04, p = 0.77 –0.01, p = 0.92
Labours [number] –0.13, p = 0.42 –0.36, p = 0.02 0.38, p = 0.01
Abortions [number] –0.34, p = 0.03 –0.06, p = 0.69 –0.01, p = 0.95
Regular of menstruation cycle [%] –0.05, p = 0.72 –0.31, p = 0.04 0.37, p = 0.01
Length of menstrual cycle [day] 0.29, p = 0.08 0.27, p = 0.10 –0.20, p = 0.24
Duration of menstrual bleeding [day] –0.06, p = 0.73 0.09, p = 0.60 –0.23, p = 0.21
FSH [mIU/ml] 0.13, p = 0.39 0.14, p = 0.35 –0.10, p = 0.50
LH [mIU/ml] 0.02, p = 0.88 0.22, p = 0.16 –0.30, p = 0.05
E2 [pg/ml] –0.02, p = 0.90 –0.07, p = 0.63 0.07, p = 0.65
PRL [ng/ml] –0.07, p = 0.66 0.08, p = 0.60 –0.11, p = 0.45
Testosterone [ng/ml] 0.07, p = 0.67 –0.07, p = 0.66 0.02, p = 0.98
sICAM-1 [ng/ml] 0.19, p = 0.23 0.05, p = 0.72 0.0, p = 0.98
Thickness of endometrium  0.18, p = 0.52 0.67, p = 0.007 –0.52, p = 0.05
in US Examination [mm]
Diameter of follicle [mm] –0.20, p = 0.37 0.23, p = 0.28 –0.43, p = 0.04
Table II. Correlations (RS) between various parameters obtained from studies on women with primary sterility and
the concentration of p55 and p75 TNF-α  receptors as well as their ratios
Figure  1.  Relationship between the number of
miscarriages and the concentration of p55 TNF-α
receptor.
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Figure  2. Relationship between the number of
deliveries and the concentration of p75 TNF-α
receptor.
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which influences ovarian activity. An environment
rich in androgens influences the procavity follicle,
inhibiting the activity of aromatase. The follicle
becomes androgenic, and finally arthritic. The
appropriate response of endometrium to the release
of progesterone in the luteal phase depends on the
activity of oestrogens and the level of their
aromaticity. Their changes are important for correct
ovulation, fertilization, and egg cell implantation.
Our studies support the idea that soluble p55
and p75 TNF-α receptors play a crucial role in
regulation of foetal development, the immune
response and hormone homeostasis. Their
increased concentrations in blood serum can lead
to ovulation disorders, implantation disorders and,
most importantly, to sterility in women. Our results
have provided evidence that supports these
speculations. We have found statistically significant
correlations between thickness of endometrium,
size of the growth ovarian vesicular and the
concentration of soluble p75 TNF-α receptor as well
as the p55/p75 TNF-α receptor ratio.
According to Weinberg [27], increased
concentration of GM-CSF can lead to infertility, due
to macrophage activation. The same mechanism
takes place in the liquid of ovulation vesicular,
which as a result can lead to decreased ability of
oocytes to become fertilized.
Weinberg also claims that activation of
macrophages (or some other cells) leads to
increased release of GM-CSF and to oocyte
maturation disorders, caused by TNF-α activation.
Our research shows correlations between LH release,
fertility and soluble p55/p75 TNF-α receptor ratios.
According to Putowski [28], only endometrium
appropriately prepared in the luteal phase is capa  -
ble of accepting a developing blastocyst and only
during a normal cycle. He claims that the mi  -
croenvironment of the endometrium (including the
immunocompetent cells) mostly influences the
hormonal proteins, growth factors, lymphokines,
prostaglandin and PAF. Some other resources show
that PAF release has a direct impact on TNF-α,
which might be the cause of infertility [1, 26, 29].
Figure  3. Relationship between the number of
deliveries and the ratio of p55/p75 concentrations  
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Figure 4. Relationship between LH concentration and
the ratio of p55/p75 concentrations
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Figure  5.  Relationship between thickness of
endometrium (USG values) and the concentration
of p75 TNF-α receptor
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Figure  6.  Relationship between thickness of
endometrium (USG values) and the ratio of p55/p75
concentrations  
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Our research provides evidence for the influence
of soluble p55 and p75 TNF-α receptors on fertility
disorders in women. Correlations between thickness
of endometrium, size of the dominant follicle, LH
concentration and concentrations of these two
receptors (as well as their ratio) might determine
the survival of vascular or lead to hyperexpression
of factors that lead to atresia.
Despite the fact that our research covers only
a small group of patients and that the results
require extended and randomised clinical studies,
they may contribute to our understanding of the
complex problem of aetiopathogenesis of infertility
in women.
In conclusion:
1) we estimated correlations between thickness of
endometrium, size of the dominant follicle, LH
concentration and the concentrations of soluble
p55 and p75 TNF-α receptors and their ratio,
2) results from the statistical analysis show no
significant statistical relationship between p55
and p75 TNF-α receptor concentrations, mean
age, BMI, length of menstrual cycle or time of
menstruation,
3)  statistical analysis of the relations of
TNFR1/TNFR2 receptor concentrations shows
a significant correlation between these receptors
and concentration of LH (p = 0.05).
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